[go: up one dir, main page]

MX2016009625A - Proteinas quimericas tipo fosfatasa alcalina. - Google Patents

Proteinas quimericas tipo fosfatasa alcalina.

Info

Publication number
MX2016009625A
MX2016009625A MX2016009625A MX2016009625A MX2016009625A MX 2016009625 A MX2016009625 A MX 2016009625A MX 2016009625 A MX2016009625 A MX 2016009625A MX 2016009625 A MX2016009625 A MX 2016009625A MX 2016009625 A MX2016009625 A MX 2016009625A
Authority
MX
Mexico
Prior art keywords
proteins
alkaline phosphatase
chimeric
chimeric alkaline
alkaline phosphatases
Prior art date
Application number
MX2016009625A
Other languages
English (en)
Other versions
MX369041B (es
Inventor
Raaben Willem
Johannes Cornelius Jonk Luigi
Jan VAN DEN BERG Erik
Luis MILLÁN José
Van Elsas Andrea
Original Assignee
Am-Pharma B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Am-Pharma B V filed Critical Am-Pharma B V
Publication of MX2016009625A publication Critical patent/MX2016009625A/es
Publication of MX369041B publication Critical patent/MX369041B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03001—Alkaline phosphatase (3.1.3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)

Abstract

La invención se refiere a la mejora de las fosfatasas alcalinas, composiciones farmacéuticas que comprenden las fosfatasas alcalinas mejoradas y el uso de las fosfatasas alcalinas mejoradas para la prevención, tratamiento o curación de enfermedades.
MX2016009625A 2014-01-24 2015-01-26 Proteinas quimericas tipo fosfatasa alcalina. MX369041B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14152526 2014-01-24
EP14188158 2014-10-08
PCT/NL2015/050048 WO2015112017A1 (en) 2014-01-24 2015-01-26 Chimeric alkaline phosphatase-like proteins

Publications (2)

Publication Number Publication Date
MX2016009625A true MX2016009625A (es) 2017-05-01
MX369041B MX369041B (es) 2019-10-25

Family

ID=52464544

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016009625A MX369041B (es) 2014-01-24 2015-01-26 Proteinas quimericas tipo fosfatasa alcalina.

Country Status (22)

Country Link
US (4) US9926544B2 (es)
EP (2) EP3425048A1 (es)
JP (3) JP6940949B2 (es)
KR (1) KR102166110B1 (es)
CN (2) CN111778228A (es)
AU (1) AU2015209783B2 (es)
BR (1) BR112016017041B1 (es)
CA (1) CA2937328C (es)
DK (1) DK3097189T3 (es)
ES (1) ES2684639T3 (es)
HU (1) HUE039784T2 (es)
IL (1) IL246898B (es)
MX (1) MX369041B (es)
PE (1) PE20161442A1 (es)
PH (1) PH12016501441B1 (es)
PL (1) PL3097189T3 (es)
RU (1) RU2683635C2 (es)
SA (1) SA516371532B1 (es)
SG (1) SG11201606060WA (es)
SI (1) SI3097189T1 (es)
WO (1) WO2015112017A1 (es)
ZA (1) ZA201605028B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3097189T3 (pl) 2014-01-24 2018-11-30 Am-Pharma B.V. Chimeryczne białka podobne do alkalicznej fosfatazy
US10822596B2 (en) 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
CA2967851C (en) 2014-12-05 2024-02-27 Alexion Pharmaceuticals, Inc. Treating seizure with recombinant alkaline phosphatase
US10603361B2 (en) 2015-01-28 2020-03-31 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
RU2745528C2 (ru) * 2015-08-17 2021-03-26 Алексион Фармасьютикалз, Инк. Производство щелочных фосфатаз
WO2017074466A1 (en) 2015-10-30 2017-05-04 Alexion Pharmaceuticals, Inc. Methods for treating craniosynostosis in a patient
EP3426286A4 (en) 2016-03-08 2019-12-04 Alexion Pharmaceuticals, Inc. PROCESS FOR TREATING HYPOPHOSPHATASIA IN CHILDREN
JP7613826B2 (ja) 2016-04-01 2025-01-15 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼによって筋力低下を治療すること
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
EP3345614A1 (en) * 2017-01-05 2018-07-11 Amrif B.V. Composition comprising alkaline phosphatase for use in the treatment of arthritides
CA3057502A1 (en) 2017-03-31 2018-10-04 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia (hpp) in adults and adolescents
EP3737750B1 (en) * 2018-01-09 2024-06-05 Theriva Biologics, Inc. Alkaline phosphatase agents for treatment of neurodevelopmental disorders
EP3762018B1 (en) 2018-03-08 2024-02-14 AM-Pharma B.V. Recombinant alkaline phosphatase for use in treating sepsis-associated acute kidney injury
US11638699B2 (en) 2018-03-20 2023-05-02 Theriva Biologics, Inc. Intestinal alkaline phosphatase formulations
WO2019183209A1 (en) 2018-03-20 2019-09-26 Synthetic Biologics, Inc. Alkaline phosphatase agents for treatment of radiation disorders
JP2021519590A (ja) 2018-03-30 2021-08-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 糖タンパク質の製造
CN110499284A (zh) * 2018-05-17 2019-11-26 西安组织工程与再生医学研究所 Wnt信号通路激活剂在制备治疗基因ALPL敲除小鼠牙硬组织矿化异常产品中的应用
JP2021534111A (ja) 2018-08-10 2021-12-09 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼを用いて神経線維腫症１型および関連状態を治療する方法
CA3137045A1 (en) 2019-05-06 2020-11-12 Synthetic Biologics, Inc. Alkaline phosphate-based oncology treatments
US12433938B2 (en) 2019-12-09 2025-10-07 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
US12478662B2 (en) * 2020-01-03 2025-11-25 The United States of America as represented by the Secretary Department of Heath and Human Services TNAP locally administered for promoting periodontal health
CN111110835A (zh) * 2020-01-22 2020-05-08 李鑫荣 一种肠碱性磷酸酶的新应用及其制剂的细胞活性检测方法
JP2023541852A (ja) 2020-09-09 2023-10-04 アーエム－ファルマ ベー．フェー． 急性呼吸窮迫症候群の治療に使用するための組換えアルカリホスファターゼ
AU2022218782A1 (en) 2021-02-12 2023-08-17 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
CN118580341B (zh) * 2024-06-24 2025-03-18 浙江大学 一种寄生线虫spi-i8蛋白及其在防治炎症疾病中的应用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8328918D0 (en) 1983-10-28 1983-11-30 Unilever Plc Alkaline phosphatase
DE69127482T2 (de) 1990-02-07 1998-03-19 Abbott Lab Alkalische Phosphatase mit verbesserter spezifischer Aktivität zur Verwendung in Indikatorreagenzien
EP0584343B1 (en) 1992-03-10 1999-01-20 La Jolla Cancer Research Foundation Recombinant calf intestinal alkaline phosphatase
JPH06284885A (ja) * 1993-04-02 1994-10-11 Tosoh Corp 組換えヒト小腸アルカリフォスファタ−ゼ
JPH08511005A (ja) 1993-06-01 1996-11-19 コーテックス ファーマシューティカルズ インコーポレイテッド 神経疾患の治療におけるアルカリ性または酸性ホスファターゼインヒビター
WO1995005455A1 (en) 1993-08-13 1995-02-23 Rijksuniversiteit Te Groningen Pharmaceutical composition comprising phosphatase or a derivative thereof
WO1995013824A1 (en) 1993-11-15 1995-05-26 Celtrix Pharmaceuticals, Inc. Method of treating renal disease by administering igf-i and igfbp-3
MXPA97009909A (es) 1995-06-06 2004-08-23 Gensci Regeneration Lab Inc Materiales osteogenicos modificados.
FR2736065B1 (fr) 1995-06-29 1997-09-19 Commissariat Energie Atomique Phosphatases alcalines bacteriennes modifiees et leurs applications.
JP3488327B2 (ja) 1995-12-21 2004-01-19 よつ葉乳業株式会社 牛乳脂肪球膜含有画分の製造法
US20020114802A1 (en) 1998-02-10 2002-08-22 Tjellstrom Bo Arthur Einar Oral immunoglobulin treatment for inflammatory bowel disease
DE19819962A1 (de) 1998-05-05 1999-11-11 Roche Diagnostics Gmbh Hochaktive alkalische Phosphatase
HK1041048A1 (zh) 1998-12-21 2002-06-28 Stichting Voor De Technische Wetenschappen 用碱性磷酸酶的lps結合部分診斷膿毒症
JP2000350596A (ja) 1999-06-11 2000-12-19 Toyobo Co Ltd 分泌性アルカリフォスファターゼの選択的活性測定方法
IL141120A0 (en) 2000-01-31 2002-02-10 Pfizer Prod Inc Use of prostaglandin (pge2) receptor 4 (epa) selective agonists for the treatment of acute and chronic renal failure
CA2415954A1 (en) 2000-07-19 2003-01-17 Kazuhiro Maeda Sulfonic acid derivatives of hydroxamic acids and their use as medicinal products
EP1191097A1 (en) 2000-09-21 2002-03-27 Leids Universitair Medisch Centrum Induction of exon skipping in eukaryotic cells
DE10101793A1 (de) 2001-01-17 2002-08-01 Manfred Nilius Verwendung von SLPI zur Behandlung chronisch-entzündlicher Darmerkrankungen
EP1370642A2 (en) 2001-01-20 2003-12-17 Cardion AG Pluripotent adult stem cells derived from regenerative tissue
WO2002098433A1 (en) 2001-06-01 2002-12-12 Ajinomoto Co., Inc. Drugs for intestinal diseases
US7157260B2 (en) 2001-07-26 2007-01-02 Japan Science & Technology Agency Nicotianamine synthase and gene encoding the same
JP4169966B2 (ja) 2001-11-14 2008-10-22 株式会社ヤクルト本社 炎症性腸疾患予防治療剤
CN1425766A (zh) 2001-12-19 2003-06-25 复旦大学 一种多肽——人含碱性磷酸酶活性位点的蛋白－9.24和编码这种多肽的多核苷酸
WO2004044178A2 (en) * 2002-11-13 2004-05-27 Genentech, Inc. Methods and compositions for diagnosing dysplasia
US7048914B2 (en) 2002-12-12 2006-05-23 Zoltan Laboratories Placental alkaline phosphatase to control diabetes
WO2004056987A1 (en) * 2002-12-23 2004-07-08 Rijksuniversiteit Groningen Modulation of the thioredoxin pathway
CA2524255C (en) 2003-03-21 2014-02-11 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
JP4305071B2 (ja) 2003-06-30 2009-07-29 株式会社ニコン 信号補正方法
JP2005065564A (ja) 2003-08-22 2005-03-17 Hiroshi Ueda センサー蛋白質
US7157261B2 (en) 2003-10-27 2007-01-02 Canji, Inc. Rat secreted embryonic alkaline phosphatase
WO2005074978A1 (en) 2004-02-04 2005-08-18 Pharmaaware Sepsis B.V. Use of alkaline phosphatase for the detoxification of lps present at mucosal barriers
US20110142817A1 (en) 2004-02-04 2011-06-16 Pharmaaware Sepsis B.V. Means and method for treating and/or preventing necrotizing enterocolitis
AU2006220772A1 (en) 2005-03-04 2006-09-14 Verenium Corporation Nucleic acids and proteins and methods for making and using them
US20070059300A1 (en) 2005-09-12 2007-03-15 Zoltan Laboratories Llc Compounds and compositions to control abnormal cell growth
EP1965830B1 (en) 2005-12-28 2014-05-14 Zoltan Laboratories Llc Use of alkaline phosphatase to maintain healthy tissue mass in mammals
RU2006103770A (ru) * 2006-02-08 2007-08-20 Тихоокеанский Институт Биоорганической Химии Дальневосточного Отделения Российской Академии Наук (Тибох Дво Ран) (Ru) Высокоактивная бактериальная щелочная фосфатаза и фрагмент днк, кодирующий щелочную фосфатазу
US20070280922A1 (en) 2006-06-06 2007-12-06 Zoltan Kiss Consulting Combinations of human proteins to enhance viability of stem cells and progenitor cells
US7718170B2 (en) 2006-08-21 2010-05-18 Essential Skincare, Llc Alkaline phosphatase compositions to reduce skin cancer
EP1952823A1 (en) 2007-01-30 2008-08-06 AM-Pharma B.V. The use of alkaline phosphatase in the treatment of reduced renal function
WO2008104199A1 (en) 2007-03-01 2008-09-04 Gelato Corporation N.V. Use of ecto-phosphatases for the treatment of (acute) myocardial infarction
EP1985697A1 (en) 2007-04-27 2008-10-29 AM-Pharma B.V. Modified phosphatases
PL2158319T4 (pl) * 2007-05-11 2016-04-29 Alexion Pharma Inc Fosfataza alkaliczna kierowana do kości, zestawy i zastosowanie
EP2030980A1 (en) 2007-08-28 2009-03-04 AM-Pharma B.V. Mutants of lactoferrin
US8784805B2 (en) 2008-02-29 2014-07-22 Alloksys Life Sciences B.V. Method for increasing the activity of the immune system of a mammal at risk of inflammatory diseases
CA2723424A1 (en) 2008-05-19 2009-11-26 Burnham Institute For Medical Research Intestinal alkaline phosphatase modulators and uses thereof
CA2732438A1 (en) 2008-08-29 2010-03-04 The General Hospital Corporation Methods of modulating gastrointestinal tract flora levels with alkaline phosphatase
AU2011245005A1 (en) * 2010-04-30 2012-11-22 Alexion Pharma Holding Methods, compositions, and kits for the treatment of matrix mineralization disorders
PL3222286T3 (pl) 2011-06-08 2021-04-06 Am-Pharma B.V. Stosowanie fosfatazy alkalicznej do zachowywania czynności nerek
CA2936829C (en) 2014-01-24 2024-05-28 Am-Pharma B.V. Downstream processing of an alkaline phosphatase
PL3097189T3 (pl) 2014-01-24 2018-11-30 Am-Pharma B.V. Chimeryczne białka podobne do alkalicznej fosfatazy

Also Published As

Publication number Publication date
KR102166110B1 (ko) 2020-10-16
CN111778228A (zh) 2020-10-16
JP6940949B2 (ja) 2021-09-29
JP7408734B2 (ja) 2024-01-05
JP2020058375A (ja) 2020-04-16
SG11201606060WA (en) 2016-08-30
MX369041B (es) 2019-10-25
CN106164262B (zh) 2020-08-07
JP2022160503A (ja) 2022-10-19
PL3097189T3 (pl) 2018-11-30
US20170009216A1 (en) 2017-01-12
ZA201605028B (en) 2020-02-26
US20240174994A1 (en) 2024-05-30
US20210163905A1 (en) 2021-06-03
US9926544B2 (en) 2018-03-27
CA2937328C (en) 2022-09-27
HUE039784T2 (hu) 2019-02-28
IL246898A0 (en) 2016-09-29
CA2937328A1 (en) 2015-07-30
PH12016501441B1 (en) 2023-02-22
CN106164262A (zh) 2016-11-23
PH12016501441A1 (en) 2016-08-22
EP3097189A1 (en) 2016-11-30
US10822597B2 (en) 2020-11-03
SA516371532B1 (ar) 2019-02-11
SI3097189T1 (sl) 2018-10-30
US11746340B2 (en) 2023-09-05
AU2015209783B2 (en) 2020-10-01
EP3097189B1 (en) 2018-07-11
DK3097189T3 (en) 2018-09-03
JP2017505128A (ja) 2017-02-16
US20190024062A1 (en) 2019-01-24
BR112016017041A2 (pt) 2017-10-03
IL246898B (en) 2019-09-26
RU2683635C2 (ru) 2019-03-29
BR112016017041B1 (pt) 2023-09-26
EP3425048A1 (en) 2019-01-09
WO2015112017A1 (en) 2015-07-30
ES2684639T3 (es) 2018-10-03
RU2016131879A (ru) 2018-03-01
RU2016131879A3 (es) 2018-08-16
KR20160117487A (ko) 2016-10-10
PE20161442A1 (es) 2017-01-12
NZ722253A (en) 2021-11-26
AU2015209783A1 (en) 2016-08-04

Similar Documents

Publication Publication Date Title
MX2016009625A (es) Proteinas quimericas tipo fosfatasa alcalina.
MX2022009148A (es) Composiciones y metodos para el tratamiento de hemoglobinopatias.
CA3024448C (en) Modulatory polynucleotides
PE20180243A1 (es) Composiciones que comprenden cepas bacterianas
EA201691582A1 (ru) Новые фармацевтические препараты
EA201790273A1 (ru) Флагеллиновые композиции и их применение
BR112017009497A2 (pt) polinucleotídeos de aadc para o tratamento da doença de parkinson
EP3263132C0 (en) Composition for treating il-6-related diseases
MX2017006283A (es) Peptidos macrociclicos utiles como inmunomoduladores.
TW201613901A (en) New compounds
MX367521B (es) Composiciones de insulina de rápida acción.
CA3015585C (en) Pth prodrugs
BR112016025819A2 (pt) vetores de vírus adeno-associados para o tratamento de doenças de depósito lisossômico
MX389447B (es) Composiciones y métodos para anticuerpos dirigidos a bmp6.
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
BR112016018062A8 (pt) compostos terapêuticos, composição farmacêutica e usos
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
BR112017007414A2 (pt) combinações compreendendo siponimod e laquinimod para o tratamento de esclerose múltipla
CR20170005A (es) Derivados de insoindolina
MX2016012784A (es) Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones.
MX2019001634A (es) Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos.
CL2019001053A1 (es) Formulaciones farmacéuticas y métodos para prepararlas.
MX387661B (es) Composiciones y métodos para el tratamiento de lesiones cutáneas precancerosas.
UY36221A (es) Derivados de isoindolinona
MX391474B (es) Péptidos cíclicos derivados de cd44v6 para el tratamiento de enfermedades relacionadas con cánceres y angiogénesis

Legal Events

Date Code Title Description
FG Grant or registration